WHO warns drug resistance could kill 39 million people by 2050
WHO officials say progress against antimicrobial resistance is too slow, putting surgery and childbirth at risk and hitting West Asia and North Africa hard.
-
This 2019 illustration provided by the Centers for Disease Control and Prevention depicts carbapenem-resistant Enterobacteriaceae (CRE) bacteria (Stephanie Rossow/CDC via AP)
Antimicrobial resistance (AMR) could cause 39 million deaths over the next 25 years and make routine surgery and childbirth life-threatening, the World Health Organization (WHO) warned on Monday.
WHO officials noted that efforts to prevent infections, test for them, and use antibiotics responsibly are moving too slowly to reach the global targets set for 2030.
Jean-Pierre Nyemazi, a senior WHO official working on AMR, told the 6th Annual Global Media Forum on AMR, held online ahead of World AMR Awareness Week (November 18 to 24), that drug resistance now threatens the future of modern medicine.
Unlike COVID-19, he said, drug-resistant infections have been “taking people’s lives for years” with little public alarm. The projection of 39 million deaths comes from the Lancet’s Global Research on Antimicrobial Resistance (GRAM) study, which the WHO and its partners cite.
Countries have plans, few have funded them
A review of 183 countries this year found that nearly nine in ten now have a national action plan against AMR, up from about four in ten in 2017. WHO technical officer Pravarsha Prakash said only 42 of them have a plan that is financed, put into practice, and monitored.
Progress is happening in every area, she stated, but it must speed up to meet the 2030 targets.
Silvia Bertagnolio, who works on AMR surveillance at the WHO, stressed that doctors without laboratory testing must treat patients without knowing what caused the infection or which drug will work.
The WHO released two new tools to help countries close that gap, one setting out the tests every level of the health system should offer and another listing laboratory procedures from sample collection to pathogen identification and antibiotic susceptibility testing.
The latest surveillance data show why testing matters. In 2023, one in six laboratory-confirmed bacterial infections reported to the WHO resisted the antibiotics used against it.
How resistance develops
Resistance is a natural process. Bacteria, viruses, fungi, and parasites change over time and stop responding to the medicines meant to kill them, but human behavior accelerates this process.
The WHO identifies the misuse and overuse of antimicrobials in people, animals, and crops as the main driver; for example, taking antibiotics for colds and flu, which they cannot treat, or giving them to livestock to promote growth.
Weak infection control, poor sanitation, and limited access to vaccines, diagnostics, and medicines let resistant microbes spread.
Why it is so dangerous
When antibiotics fail, infections last longer, spread more easily, and kill more often. Surgery, childbirth, organ transplants, and cancer chemotherapy all depend on drugs that can stop infection, so each becomes riskier.
In 2021, AMR directly caused more than one million deaths and contributed to about 4.7 million others, according to WHO figures.
Resistance is already eroding first-choice treatments for serious infections. Globally, more than 40% of E. coli and over 55% of K. pneumoniae cases resist third-generation cephalosporins, which are the standard treatment.
Resistance to carbapenems, once rare, is also becoming more common, pushing doctors toward costly last-resort drugs that many poorer countries cannot easily obtain.
Can it be treated?
Resistant infections can often still be treated, but with fewer, more expensive options and a shrinking supply of new drugs.
The WHO counted 90 antibacterial agents in clinical development in early 2025, down from 97 two years earlier. Only 15 of them are considered innovative, and just five work against at least one of the bacteria the WHO ranks as most critical.
The agency said the strongest tools remain prevention and careful use. It named infection prevention, vaccination, better access to clean water and sanitation, and the appropriate use of antimicrobials as the main levers.
Resistance in West Asia, North Africa
The WHO’s Eastern Mediterranean Region, which covers much of West Asia and North Africa, has among the highest resistance levels in the world. Its 2025 surveillance report found that about one in three reported infections in the region and in South-East Asia were resistant, roughly double the global average. In the African region, one in five infections was resistant.
War compounds the problem. Researchers say conflict spreads infection through overcrowding, damaged water systems, and overwhelmed hospitals, and encourages antibiotic misuse.
Médecins Sans Frontières found that 86.2% of Enterobacteriaceae isolates from war-wounded patients resisted third-generation cephalosporins.
Governments will take up the issue at the Fifth Global High-Level Ministerial Conference on Antimicrobial Resistance in Abuja, Nigeria, on December 6 to 8.